{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:13:50Z","timestamp":1754162030087,"version":"3.41.2"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>A growing evidence on the correlation between hyperuricemia and cardiovascular disease (CVD) has been previously reported. However, there have been limited data on the impact of hyperuricemia on long-term clinical outcomes in patients with critical limb ischemia (CLI) who underwent percutaneous transluminal angioplasty (PTA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 425 peripheral artery disease patients who underwent PTA for CLI were enrolled. The patients were divided into the hyperuricemia group (n\u2005=\u2005101) and the normal group (n\u2005=\u2005324). The primary endpoint was major adverse cerebral and cardiovascular event (MACCE), including death, myocardial infarction, any coronary revascularization, and stroke, up to 5 years. The secondary endpoint was a major adverse limb event (MALE), including any repeated PTA, and target extremity surgery. Inverse probability weighting (IPTW) analysis, derived from the logistic regression model, was performed to adjust for potential confounders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>After IPTW matching analysis, compared to the normal group, the hyperuricemia group was associated with a higher incidence of MACCE (20.7% vs. 13.6%, hazard ratio [HR], 1.65; 95% confidence interval [CI], 1.15\u20132.38, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.006) including non-cardiac death (11.7% vs. 6.3%, HR: 1.95, 95% CI: 1.19\u20133.19, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.006) and MALE (47.7% vs. 36.0%, HR: 1.62, 95% CI: 1.23\u20132.13, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.001) including non-target extremity revascularization (15.0% vs. 6.8%, HR: 2.42, 95% CI: 1.52\u20133.84, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In the present study, hyperuricemia was associated with worse clinical outcomes in patients with CLI following PTA during 5-year clinical follow-up. Efficacy of controlling hyperuricemia in improving clinical outcomes should be evaluated in further studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001354","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T12:11:17Z","timestamp":1709813477000},"page":"201-208","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of hyperuricemia on 5-year clinical outcomes in patients with critical limb ischemia following percutaneous transluminal angioplasty"],"prefix":"10.1097","volume":"35","author":[{"given":"Seong Joon","family":"An","sequence":"first","affiliation":[{"name":"Korea University College of Medicine, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Jin","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tongyeong Detention Center, Korea Correctional Service, Ministry of Justice, Tongyeong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soohyung","family":"Park","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Jin","family":"Hyun","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Korea University, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Ah","family":"Cha","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Korea University, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Kyeong","family":"Byun","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Korea University, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Yeon","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Korea University, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol Ung","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Joo","family":"Oh","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Korea University, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Geol","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Korea University, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tcm.2019.04.002","article-title":"Lower extremity critical limb ischemia: a review of clinical features and management.","volume":"30","author":"Levin","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS).","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrcardio.2016.179","article-title":"Peripheral artery disease: epidemiology and global perspectives.","volume":"14","author":"Fowkes","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the american heart association.","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jare.2017.03.003","article-title":"Physiological functions and pathogenic potential of uric acid: a review.","volume":"8","author":"El Ridi","year":"2017","journal-title":"J Adv Res"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"E827","DOI":"10.1152\/ajpendo.00378.2020","article-title":"New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.","volume":"319","author":"Furuhashi","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.0000150784.92944.9a","article-title":"Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence.","volume":"45","author":"Sundstr\u00f6m","year":"2005","journal-title":"Hypertension"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk.","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.amjcard.2005.07.068","article-title":"Status of endothelial dependent vasodilation in patients with hyperuricemia.","volume":"96","author":"Kato","year":"2005","journal-title":"Am J Cardiol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ajh.2011.55","article-title":"Relationships among hyperuricemia, metabolic syndrome, and endothelial function.","volume":"24","author":"Tomiyama","year":"2011","journal-title":"Am J Hypertens"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/eurheartj\/ehi879","article-title":"Uric acid and inflammatory markers.","volume":"27","author":"Ruggiero","year":"2006","journal-title":"Eur Heart J"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.mnh.0000199010.33929.7f","article-title":"Hormonal and cytokine effects of uric acid.","volume":"15","author":"S\u00e1nchez-Lozada","year":"2006","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000087713","article-title":"Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter.","volume":"25","author":"Kang","year":"2005","journal-title":"Am J Nephrol"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.atherosclerosis.2006.12.029","article-title":"Association between serum uric acid level and peripheral arterial disease.","volume":"196","author":"Shankar","year":"2008","journal-title":"Atherosclerosis"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"725","DOI":"10.5551\/jat.37010","article-title":"Association of serum uric acid levels with leg ischemia in patients with peripheral arterial disease after treatment.","volume":"24","author":"Sotoda","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0021-9150(03)00093-5","article-title":"Serum uric acid in hypertensive patients with and without peripheral arterial disease.","volume":"168","author":"Langlois","year":"2003","journal-title":"Atherosclerosis"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/01.HYP.0000254480.64564.b6","article-title":"Hyperuricemia and incidence of hypertension among men without metabolic syndrome.","volume":"49","author":"Krishnan","year":"2007","journal-title":"Hypertension"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.2174\/1381612811319130011","article-title":"Chronic hyperuricemia, uric acid deposit and cardiovascular risk.","volume":"19","author":"Grassi","year":"2013","journal-title":"Curr Pharm Des"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia.","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2011-201254","article-title":"Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study.","volume":"72","author":"Trifir\u00f2","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","article-title":"Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.","volume":"131","author":"Culleton","year":"1999","journal-title":"Ann Intern Med"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1371\/journal.pmed.0020076","article-title":"Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis.","volume":"2","author":"Wheeler","year":"2005","journal-title":"PLoS Med"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","article-title":"Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.","volume":"80","author":"Borghi","year":"2020","journal-title":"Eur J Intern Med"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","article-title":"Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?","volume":"41","author":"Johnson","year":"2003","journal-title":"Hypertension"},{"key":"R26-20250729","first-page":"370","article-title":"How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations.","volume":"17","author":"Pan","year":"2008","journal-title":"Asia Pac J Clin Nutr"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective.","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ Res"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"e009459","DOI":"10.1161\/CIRCINTERVENTIONS.120.009459","article-title":"Sex differences in management and outcomes of critical limb ischemia in the medicare population.","volume":"13","author":"Mentias","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/eurheartj\/ehl545","article-title":"A call for uniform reporting standards in studies assessing endovascular treatment for chronic ischaemia of lower limb arteries.","volume":"28","author":"Diehm","year":"2007","journal-title":"Eur Heart J"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJMcp1709326","article-title":"Chronic limb-threatening ischemia.","volume":"379","author":"Farber","year":"2018","journal-title":"N Engl J Med"},{"issue":"1, Supplement","key":"R31-20250729","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia.","volume":"58","author":"Conte","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"12394","DOI":"10.3390\/ijms222212394","article-title":"Uric acid in inflammation and the pathogenesis of atherosclerosis.","volume":"22","author":"Kimura","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurheartj\/ehl441","article-title":"Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study.","volume":"28","author":"Tzoulaki","year":"2007","journal-title":"Eur Heart J"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/01.CIR.97.5.425","article-title":"Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.","volume":"97","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"F625","DOI":"10.1152\/ajprenal.00140.2005","article-title":"A causal role for uric acid in fructose-induced metabolic syndrome.","volume":"290","author":"Nakagawa","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.3390\/ijms22179221","article-title":"Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease.","volume":"22","author":"Yanai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"107904","DOI":"10.1155\/2011\/107904","article-title":"Relationship between serum concentration of uric acid and insulin secretion among adults with type 2 diabetes mellitus.","volume":"2011","author":"Robles-Cervantes","year":"2011","journal-title":"Int J Endocrinol"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:03:13Z","timestamp":1753812193000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001354","relation":{},"ISSN":["0954-6928"],"issn-type":[{"type":"print","value":"0954-6928"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}